- Home
- CUE vs REKR Comparison
CUE vs REKR Comparison
Compare CUE & REKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- REKR
- Stock Information
- Founded
- CUE 2014
- REKR 2017
- Country
- CUE United States
- REKR United States
- Employees
- CUE N/A
- REKR N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- REKR Telecommunications Equipment
- Sector
- CUE Health Care
- REKR Telecommunications
- Exchange
- CUE Nasdaq
- REKR Nasdaq
- Market Cap
- CUE 77.3M
- REKR 79.8M
- IPO Year
- CUE 2018
- REKR N/A
- Fundamental
- Price
- CUE $1.07
- REKR $0.84
- Analyst Decision
- CUE Strong Buy
- REKR Buy
- Analyst Count
- CUE 5
- REKR 1
- Target Price
- CUE $5.00
- REKR N/A
- AVG Volume (30 Days)
- CUE 378.2K
- REKR 903.8K
- Earning Date
- CUE 11-14-2024
- REKR 11-14-2024
- Dividend Yield
- CUE N/A
- REKR N/A
- EPS Growth
- CUE N/A
- REKR N/A
- EPS
- CUE N/A
- REKR N/A
- Revenue
- CUE $9,532,000.00
- REKR $43,817,000.00
- Revenue This Year
- CUE $105.39
- REKR $33.40
- Revenue Next Year
- CUE N/A
- REKR $41.09
- P/E Ratio
- CUE N/A
- REKR N/A
- Revenue Growth
- CUE 149.53
- REKR 44.46
- 52 Week Low
- CUE $0.45
- REKR $0.79
- 52 Week High
- CUE $3.20
- REKR $3.92
- Technical
- Relative Strength Index (RSI)
- CUE 45.52
- REKR 41.80
- Support Level
- CUE $0.92
- REKR $0.81
- Resistance Level
- CUE $1.09
- REKR $0.88
- Average True Range (ATR)
- CUE 0.11
- REKR 0.07
- MACD
- CUE 0.00
- REKR 0.00
- Stochastic Oscillator
- CUE 45.71
- REKR 25.34
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.
About REKR Rekor Systems Inc.
Rekor Systems Inc is a United States-based company. The company is engaged in providing real-time roadway intelligence through AI-driven decisions. The firm uses artificial intelligence to analyze video streams and transform them into AI-driven decisions. The company's technology and machine learning models power all solutions, including Rekor Command for transportation management, Rekor Discover for urban mobility, and Rekor Scout for public safety, and commercial use. Its geographical segments are the United States and Others, of which the majority of its revenue comes from the United States.